I have seen posts indicating that 20-30% of all ca

Quote:

---

I have seen posts indicating that 20-30% of all cancers could be CCR5+. I have not seen any estimates as to how many additional cancers could have CCR5+ cancer surrounding macrophages though. But, I know of at least one example where it is not the case, so it is not 100% of all cancers.

---

Yeah, all cancers, probably 20-30% of all cancers are ccr5+, chemo adds ccr5 though and ccr5 enables cancer to repair itself among other items that leronlimab might help even though cancer or surrounding environment is not ccr5.

Anyway though to my point, in metastatic cancer, which is responsible for 90% or so cancer deaths, that percentage is usually much higher, probably 50%-80%, and the more aggressive the cancer type, the higher the ccr5 percentage initially.

That is why when I was estimating the size of the market assuming leronlimab works in the basket trial, I used as a base estimate:
number of cancer deaths x 90% (metastatic) x 50% (metastatic that has high ccr5)